Finding Health Online
News for:   
 

   
 

For this drug, our server compiled this detailed Chemical Profile.

You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.

 

 
 
 
 

 

Click the Chemical Profile link above for detailed information.

Visit Betterchem's Drug Index for…

  • Exclusivity
    Patents and market exclusivity

  • Drug Information
    Prescribing and other information

  • DMFs
    Type 2 drug master files

  • Databases
    Free access to database search

  • 21 CFR
    FDA regulations for this drug

  • Federal Register
    FR search results for this drug

  • Drug Recalls
    For Rx's using this API

  FDA Approval Activities for this Drug…

Pravachol (Pravastatin Sodium) Tablets, Bristol-Myers Squibb NDA 19-898/S054 9/5/03 9/25/03 9/25/03 Pravachol (Pravastatin Sodium) Tablets, Bristol-Myers Squibb NDA 19-898/S052 10/29/02 11/18/02 10/29/02 Pravachol (Pravastatin Sodium) Tablets, Bristol-Myers Squibb NDA 19-898/S050 7/12/02 7/15/02 7/12/02 Pravachol (Pravastatin Sodium) Tablets, Bristol-Myers Squibb NDA 19-898/S042 6/22/01 11/6/01 11/6/01 Pravachol/Pravastatin Sodium Tablets, Bristol-Myers Squibb NDA 19-898/S034 10/14/99 10/15/99 2/22/00 Pravachol (pravastatin) Tablets, Bristol-Myers Squibb NDA 19-898/S-032 2/10/00 2/14/00 12/11/01 Pravachol Indications: This supplemental new drug application provides for a new indication, based on the results of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, for the use of pravastatin in patients with evident coronary heart disease to reduce the risk of total mortality by reducing coronary death. In addition, this supplemental application provides for changes to the CLINICAL PHARMACOLOGY and PRECAUTIONS sections of the Pravachol package insert. Pravachol (pravastatin) Tablets,Rx Bristol-Myers Squibb NDA 19-898/S-031 6/9/00 6/12/00 Pravachol Indications: This supplemental new drug application provides for the additional indication of increasing HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb). Pravachol (Pravastatin Sodium) Tablets, Bristol-Myers Squibb NDA 19-898/S018 3/27/98 5/22/01 Pravachol (Pravastatin Sodium) Tablets, Bristol-Myers Squibb NDA 19-898/S020 3/11/98 5/22/01 Pravachol/Pravastatin Sodium Tablets, Bristol-Myers Squibb 19-898/S026, S027, S029, S030 1/18/00 1/21/00 Pravachol/Pravastatin Sodium Tablets, Bristol-Myers Squibb 19-898/S026, S027, S029, S030 1/18/00 1/21/00 Pravachol Indications: These supplemental new drug applications provide for new indications for the use of Pravachol (pravastatin) tablets in the treatment of patients with Frederickson Type IV (S-026) and in the treatment of patients with Frederickson Type III (S-027). In addition, they provide for an optional starting dose of 40 mg/day (S-029) and for a change in the recommended time of dosing from administration at bedtime to administration at any time of day with or without food (S-030). 5. It is a prescription drug. Pravachol (Pravastatin) Tablets, Bristol-Myers Squibb 19-898/S034 10/14/99 7/6/00 Pravachol (Pravastatin) Tablets, Bristol-Myers Squibb 19-898/S037 6/23/00 Pravachol Indications: Change to the Clinical Pharmacology, Pharmacokinetics/Metabolism subsection regarding age-relatd differences in mean AUC and mean cumulative urinary excretion of pravastatin and for the addition of a "Geriatric Use" subsection to the Precautions section of the Provachol package insert. Pravachol (Pravastatin) Tablets, Bristol-Myers Squibb 19-898/S046 12/18/01 5/1/02 1/25/02 Pravastatin Sodium Tablets, 10, 20 40 & 80 mg, Ranbaxy ANDA 76-445 9/30/03 Pravastatin Sodium Tablets, 10, 20 & 40 mg, LEK ANDA 76-397 6/26/03 Pravastatin Sodium Tablets, 10, 20 & 40 mg, Apotex ANDA 76-341 9/30/03 Pravastatin Sodium Tablets, 10, 20, 40 & 80 mg, Geneva ANDA 76-279 1/30/03 Pravastatin Sodium Tablets, 10, 20 & 40 mg, Ivax ANDA 76-199 7/31/03 Pravastatin Sodium Tablets, 10, 20 & 40 mg, Teva ANDA 76-056 Pravigard PAC (co-packaged 20, 40 or 80 mg pravastatin sodium and 81 or 325 mg buffered aspirin) Tablets, Bristol-Myers Squibb Company NDA 21-387 | Pravastatin Sodium Tablets, Genpharm, Tentative Approval | Pravachol (pravastatin sodium) Tablets, Bristol-Myers Squibb, Labeling Revision | Pravastatin Sodium Tablets, Dr. Reddy’s, Tentative Approval | Pravastatin Sodium Tablets, Teva Pharma, Approval | Pravastatin Sodium Tablets, Watson Labs, Tentative Approval | Pravastatin Sodium Tablets, Zydus Pharma, Tentative Approval | Pravastatin Sodium Tablets, Teva Pharma, Labeling Revision | Pravastatin Sodium Tablets, Lek Pharma, Approval | Pravastatin Sodium Tablets, Genpharm Inc., Approval/Tentative Approval | Pravastatin Sodium Tablets, Watson Labs, Approval/Tentative Approval | Pravastatin Sodium Tablets, Cobalt Pharma, Approval/Tentative Approval | Pravastatin Sodium Tablets, Dr. Reddy’s Labs, Approval/Tentative Approval | Pravastatin Sodium Tablets, Apotex Inc., Approval/Tentative Approval | Pravastatin Sodium Tablets, Lek Pharma, Tentative Approval | Pravastatin Sodium Tablets, Teva Pharma, Tentative Approval | Pravachol (pravastatin sodium) Tablets, Bristol Myers Squibb, Efficacy Supp. w/Clinical Data

Visit Betterchem's Drug Index for FDA's latest approval information.


 

Find other drugs…

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z

Health Topics | News Feed for each API | USActives.com | Pharma Job Search | Pharma Company News

© 2011 FindingHealthOnline